CLINICAL RELEVANCE: DRUG–DRUG INTERACTION,PHARMACOKINETICS,PHARMACODYNAMICS, AND TOXICITY - Drug Transporters: Molecular Characterization and Role in Drug Disposition - page 873

867. Jarvis SM, Thorm JA, Glue P. 1998. Ribavirin uptake by human erythrocytes and
the involvement of nytrobenzylthioinosine-sensitive (es)-nucleoside transporters. Br J
Pharmacol 123: 1587-1592.
868. Mackey JR, Mani RS, Selner M, Mowles D, Young JD, Belt JA, Crawford CR, Cass
CE. 1998. Functional nucleoside transporters are required for gemcitabine influx and
manifestation of toxicity in cancer cell lines. Cancer Res 58: 4349-4357.
869. Mackey JR, Yao SY, Smith KM, Karpinski E, Baldwin SA, Cass CE, Young JD. 1999.
Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane
mammalian nucleoside transporters. J Natl Cancer Inst 91: 1876-1881.
870. Yao SY, Ng AM, Sundaram M, Cass CE, Baldwin SA, Young JD. 2001. Transport
of antiviral 3 -deoxy-nucleoside drugs by recombinant human and rat equilibrative,
nitrobenzylthioinosine (NBMPR)-insensitive (ENT2) nucleoside transporter proteins
produced in Xenopus oocytes. Mol Membr Biol 18: 161-167.
871. Patil SD, Ngo LY, Unadkat JD. 2000. Structure-inhibitory profiles of nucleosides for the
human intestinal N1 and N2 Na + -nucleoside transporters. Cancer Chemother Pharmacol
46: 394-402.
872. Crawford CR, Patel DH, Naeve C, Belt JA. 1998. Cloning of the human equilibrative,
nitrobenzylmercaptopurine riboside (NBMPR)-insensitive nucleoside transporter ei
by functional expression in a transport-deficient cell line. J Biol Chem 273: 5288-
5293.
873. Ward JL, Leung GP, Toan SV, Tse CM. 2003. Functional analysis of site directed gly-
cosylation mutants of the human equilibrative nucleoside transporter-2. Arch Biochem
Biophys 411: 19-26.
874. Guida L, Bruzzone S, Sturla L, Franco L, Zocchi E, De Flora A. 2002. Equilibrative and
concentrative nucleoside transporters mediate influx of extracellular cyclic ADP-ribose
into 3T3 murine fibroblasts. J Biol Chem 277: 47097-47105.
875. Garcia-Manteiga J, Molina-Arcas M, Casado FJ, Mazo A, Pastor-Anglada M. 2003.
Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in
2 ,2 -difluorodeoxycytidine- induced cytotoxicity. Clin Cancer Res 9: 5000-5008.
876. Molina-Arcas M, Bellosillo B, Casado FJ, Mentserrat J, Gil J, Colomer D, Pastor-
Anglada M. 2003. Fludarabine uptake mechanisms in B-cell chronic lymphocytic
leucemia. Blood 101: 2328-2334.
877. Molina-Arcas M, Marce S, Villamor N, Huber-Ruano I, Casado FJ, Bellosillo B,
Montserrat E, Gil J, Colomer D, Pastor-Anglada M. 2005. Equilibrative nucleoside
transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine
in chronic lymphocytic leukemia (CLL) cells. Leukemia 19: 64-68.
878. Baldwin SA, Beal PR, Yao SY, King AE, Cass CE, Young JD. 2004. The equilibrative
nucleoside transporter family, SLC29. Pflugers Arch 447: 735-743.
879. Baldwin SA, Yao SY, Hyde RJ, Ng AM, Foppolo S, Barnes K, Ritzel MW, Cass CE,
Young JD. 2005. Functional characterization of novel human and mouse equilibrative
nucleoside transporters (hENT3 and mENT3) located in intracellular membranes. J Biol
Chem 280: 15880-15887.
880. Ritzel MW, Yao SY, Huang MY, Elliott JF, Cass CE, Young JD. 1997. Molecular cloning
and functional expression of cDNAs encoding a human Na + -nucleoside cotransporter
(hCNT1). Am J Physiol 272: C707-C714.